RESEARCH USE AND EDUCATIONAL DISCLAIMER
This article summarizes published scientific research for educational purposes only. Level Up Peptides products are intended exclusively for laboratory research by qualified researchers and are not for human or veterinary use. Discussion of published animal or human studies does not recommend those uses or establish the safety or effectiveness of any product sold on this website. This article does not provide medical advice, dosing guidance, or administration instructions.
SUMMARY
SLU-PP-332 is a synthetic small molecule studied for activation of estrogen-related receptors, or ERRs. It is not a peptide. Published experiments connect ERR activation with exercise-related gene expression, energy metabolism and cardiac function in mice. The research is preclinical: these findings do not establish human fat loss, improved athletic performance or a replacement for exercise. This review explains three original reports and the questions they leave open. [1–3]
WHAT ERR ACTIVATION MEANS
The name estrogen-related receptor can be confusing. The studies discussed here concern ERR nuclear receptors, which regulate gene expression; they should not be read as ordinary estrogen-treatment studies. SLU-PP-332 was developed as an agonist acting across the ERR alpha, beta and gamma family. An agonist activates a receptor in the tested system. [1]
That mechanism provides a research hypothesis, not a clinical conclusion. Changes in gene activity can help explain an experimental effect, but they do not tell researchers everything about its magnitude, durability or safety in another species.
THE EXERCISE-RELATED MOUSE EXPERIMENTS
Billon and colleagues reported in 2023 that SLU-PP-332 induced an acute aerobic exercise-related gene program and improved exercise capacity in mice. Experiments using muscle-specific loss of ERR alpha helped establish that this receptor was important for the observed endurance response. [1]
This genetic comparison strengthens the mechanistic argument: it tests whether the proposed target is necessary for a response rather than simply observing that two measurements change together. It still remains evidence from experimental models.
The phrase “exercise mimetic” refers to reproducing selected biological features associated with exercise. It does not mean that a compound duplicates all the effects of physical activity, including cardiovascular conditioning, movement skills, tissue loading and broader health outcomes.
METABOLISM AND OBESITY MODELS
A subsequent report by Billon and colleagues examined SLU-PP-332 in mouse models of obesity and metabolic syndrome. The investigators reported increased energy expenditure and fatty acid oxidation, along with reduced fat accumulation and improvements in insulin sensitivity in the disease models studied. [2]
Responses depended on the experimental setting. The paper also reported that glucose metabolism did not improve in mice maintained on standard chow. That distinction argues against presenting the compound as universally improving every metabolic measurement. [2]
Animal models help isolate biological mechanisms, but they do not provide a human weight-loss estimate. Human exposure, tolerability, clinical outcomes and long-term follow-up would require their own studies. A laboratory finding cannot establish those results by extrapolation alone.
CARDIAC FUNCTION IN A PRESSURE-OVERLOAD MODEL
Xu and colleagues investigated SLU-PP-332 alongside a separate compound, SLU-PP-915, in a mouse model of pressure-overload heart failure. Both compounds improved measures of cardiac pumping, reduced fibrosis and increased survival in that model, without reducing cardiac hypertrophy. [3]
The researchers also studied metabolic pathways and receptor dependence. Their experiments identified ERR gamma as a major mediator of the cardiac effects, illustrating that the relevant receptor contribution can differ between skeletal-muscle and cardiac experiments. [3]
This is evidence supporting further drug-development research. It is not a clinical heart-failure trial, and results for the two investigational compounds should not be treated as proof that any product labeled SLU-PP-332 has the same properties.
WHAT REMAINS UNRESOLVED
The studies establish a coherent preclinical research direction involving receptor signaling and energy metabolism. They do not establish a human benefit-to-risk profile. A convincing clinical development program would need appropriate pharmacology, toxicology, controlled human studies and confirmation that the tested material is consistently characterized.
Readers should also distinguish an observed outcome from a broader marketing interpretation. Better treadmill performance in mice is an experimental endpoint. “Exercise in a bottle” is a much larger claim that those experiments do not demonstrate.
SLU-PP-332 remains a subject for qualified laboratory investigation in this educational review. None of the cited publications validates personal use of a research product or replaces batch-specific identity and quality assessment.
REFERENCES
1. Billon C, Sitaula S, Banerjee S, et al. Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity. ACS Chemical Biology. 2023;18:756–771.
https://doi.org/10.1021/acschembio.2c00720
2. Billon C, Schoepke E, Avdagic A, et al. A Synthetic ERR Agonist Alleviates Metabolic Syndrome. Journal of Pharmacology and Experimental Therapeutics. 2024;388:232–240.
https://doi.org/10.1124/jpet.123.001733
3. Xu W, Billon C, Li H, et al. Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function. Circulation. 2024;149:227–250.
https://doi.org/10.1161/CIRCULATIONAHA.123.066542